142 related articles for article (PubMed ID: 26495775)
1. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study.
Imaoka H; Mizuno N; Hara K; Hijioka S; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutsumi H; Fujiyoshi T; Sato T; Shimizu Y; Niwa Y; Yamao K
Pancreas; 2016 Feb; 45(2):211-7. PubMed ID: 26495775
[TBL] [Abstract][Full Text] [Related]
2. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma.
La Torre M; Nigri G; Cavallini M; Mercantini P; Ziparo V; Ramacciato G
Ann Surg Oncol; 2012 Sep; 19(9):2917-23. PubMed ID: 22488099
[TBL] [Abstract][Full Text] [Related]
3. Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?
Walsh SM; Casey S; Kennedy R; Ravi N; Reynolds JV
J Surg Oncol; 2016 Jun; 113(7):732-7. PubMed ID: 27004839
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and clinical significance of modified glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients.
Wu D; Wang X; Shi G; Sun H; Ge G
Aging (Albany NY); 2021 Jan; 13(1):1410-1421. PubMed ID: 33406501
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer.
Nakayama M; Tabuchi K; Hara A
Head Neck; 2015 Dec; 37(12):1745-9. PubMed ID: 24989115
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
[TBL] [Abstract][Full Text] [Related]
7. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
[TBL] [Abstract][Full Text] [Related]
8. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer.
Takeno S; Hashimoto T; Shibata R; Maki K; Shiwaku H; Yamana I; Yamashita R; Yamashita Y
Oncology; 2014; 87(4):205-14. PubMed ID: 25034097
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care.
Pantano Nde P; Paiva BS; Hui D; Paiva CE
J Pain Symptom Manage; 2016 Feb; 51(2):270-7. PubMed ID: 26598040
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer.
Inoue Y; Iwata T; Okugawa Y; Kawamoto A; Hiro J; Toiyama Y; Tanaka K; Uchida K; Mohri Y; Miki C; Kusunoki M
Oncology; 2013; 84(2):100-7. PubMed ID: 23147449
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
14. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin in Patients with Colorectal Cancer.
Shibutani M; Maeda K; Nagahara H; Iseki Y; Ikeya T; Hirakawa K
Anticancer Res; 2016 Mar; 36(3):995-1001. PubMed ID: 26976989
[TBL] [Abstract][Full Text] [Related]
16. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
[TBL] [Abstract][Full Text] [Related]
17. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
Ishizuka M; Nagata H; Takagi K; Kubota K
Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
[TBL] [Abstract][Full Text] [Related]
18. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
19. The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer.
Wu M; Guo J; Guo L; Zuo Q
Tumour Biol; 2016 Sep; 37(9):12525-12533. PubMed ID: 27344157
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
